New hair loss drug is expected to be launched to restore 80% of hair growth

On May 21, Eli Lilly and Company and Incyte announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) supported the listing of its JAK inhibitor baricitinib (Olumiant) for the Treatment of adult patients with severe alopecia area.

Alopecia areata is the second most common hair loss symptom in the world, with about 147 million patients worldwide and about 4 million in Chi.

Baricitinib, a once-daily oral JAK inhibitor, has been approved for the treatment of rheumatoid arthritis in more than 75 countries and regions and is approved for the treatment of rheumatoid arthritis in more than 50 countries and regions Severe atopic dermatit.

▲The performance of a previous patient with severe alopecia areata before treatment and after receiving baricitinib for 8 months (Image source: Reference [2])

The CHMP's positive opinion is based on the results of two Phase 3 clinical trials, BRAVE-AA1 and BRAVE-AA2, in 1,200 patients with severe alopecia area.

At the same time, about one-third of patients achieved complete regrowth of eyebrows or eyelashes or no apparent lo.

"Alopecia areata is an often misunderstood autoimmune disease that causes unpredictable hair loss and, in severe cases, loss of all ha.

In addition to baricitinib, Pfizer's JAK3/TEC inhibitor ritlecitinib, Concert Pharmaceuticals' JAK1/2 inhibitor CTP-543, Zejing Pharmaceuticals' JAK inhibitor ritlecitinib, and Restone's JAK1 inhibitor The agent SHR0302 has also achieved positive results in clinical trials and is in late-stage clinical developme.

References:

[1] CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (A.

[2] Olamiju et .